The National Comprehensive Cancer Network, an organization that promulgates guidelines based on standards of care provided at academic institutions in the U.S., is indisputably one of the pillars of oncology today.
Last year, Fox Chase Cancer Center stood poised to make history by becoming the first NCI-designated cancer center to be sold on open market.
On Monday, March 1, Adekunle “Kunle” Odunsi will become the director of the University of Chicago Comprehensive Cancer Center—and the second Black director of an NCI-designated cancer center.
Five academic cancer centers have formed a unique research alliance, Break Through Cancer, to focus on four cancer types—pancreatic cancer, ovarian cancer, glioblastoma, and acute myelogenous leukemia.
As she became president of the American Society of Clinical Oncology, Lori J. Pierce decided to focus on equity in cancer care as her year-long presidential theme.
In a matter of months, cancer researchers have gone from grappling with a surge of COVID-19 with limited clinical data to playing a critical role in the development of successful mRNA vaccines against the disease.
Being Black and running an NCI-designated cancer center at a time of a worldwide pandemic, an ugly election, and a racial reckoning in a Southern town puts you in a position to make profound observations.
Twenty-five years ago, The Cancer Letter missed a big story.
In his previous job, in North Carolina, Edward S. Kim helped build a cancer program where there was none.
Sean Khozin, a data science expert and formerly a senior medical officer at FDA, has been tapped to lead CancerLinQ—the American Society of Clinical Oncology's multimillion-dollar big data initiative designed to generate real-world evidence from patient records.
